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CARDIOLOGY/ORIGINAL RESEARCHVolume -, no.The Ambulance Cardiac Chest Pain Evaluation in
Scotland Study (ACCESS): A Prospective Cohort
Study
Jamie G. Cooper, MBChB*; James Ferguson, MBChB; Lorna A. Donaldson; Kim M. M. Black; Kate J. Livock; Judith L. Horrill, MSc;
Elaine M. Davidson, MSc, PhD; Neil W. Scott, MSc, PhD; Amanda J. Lee, PhD; Takeshi Fujisawa, PhD; Kuan Ken Lee, MD;
Atul Anand, MD, PhD; Anoop S. V. Shah, MD, PhD; Nicholas L. Mills, MD, PhD
*Corresponding Author. E-mail: jamie.cooper2@nhs.scot, Twitter: @JamieCooperEM.Study objective: To determine whether risk stratification in the out-of-hospital setting could identify patients with chest pain who
are at low and high risk to avoid admission or aid direct transfer to cardiac centers.
Methods: Paramedics prospectively enrolled patients with suspected acute coronary syndrome without diagnostic ST-segment
elevation on the ECG. The History, ECG, Age and Risk Factors (HEAR) score was recorded contemporaneously, and out-of-hospital
samples were obtained to measure cardiac Troponin I (cTnI) level on a point-of-care device, to allow calculation of the History,
ECG, Age, Risk Factors, and Troponin (HEART) score. HEAR and HEART scores less than or equal to 3 and greater than or equal to
7 were defined as low and high risk for major adverse cardiac events at 30 days.
Results: Of 1,054 patients (64 years [SD 15 years]; 42% women), 284 (27%) experienced a major adverse cardiac event at 30
days. The HEAR score was calculated in all patients, with point-of-care cTnI testing available in 357 (34%). A HEAR score less than
or equal to 3 identified 32% of patients (334/1,054) as low risk, with a sensitivity of 84.9% (95% confidence interval [CI] 80.7% to
89%), whereas a score greater than or equal to 7 identified just 3% of patients (30/1,054) as high risk, with a specificity of 98.7%
(95% CI 97.9% to 99.5%). A point-of-care HEART score less than or equal to 3 identified a similar proportion as low risk (30%), with
a sensitivity of 87.0% (95% CI 80.7% to 93.4%), whereas a score greater than or equal to 7 identified 14% as high risk, with a
specificity of 94.8% (95% CI 92.0% to 97.5%).
Conclusion: Paramedics can use the HEAR score to discriminate risk, but even when used in combination with out-of-hospital
point-of-care cTnI testing, the HEART score does not safely rule out major adverse cardiac events, and only a small proportion of
patients are identified as high risk. [Ann Emerg Med. 2021;-:1-14.]
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Chest pain suggestive of acute coronary syndrome is the
reason for more than 1 in 6 urgent ambulance transfers to
the hospital1 and is responsible for 1 in 20 presentations to
the emergency department (ED).2 Pathways incorporating
out-of-hospital ECG to identify patients with ST-segment
elevation for rapid transfer to hospitals with cardiac
catheterization facilities are now widespread.3 However, the
majority of patients do not have diagnostic ECG changes4
and immediate ambulance transfer to a secondary care
hospital is the rule, though less than 1 in 5 patients will
have a final diagnosis of myocardial infarction.2,5
Differentiation of patients with myocardial infarction from
those with other often benign causes of chest pain by using- : - 2021cardiac troponin testing at the point of care is feasible,6-8
improving time to definitive treatment and potentially
reducing the need for ambulance hospital transfers.9 The
effect of adopting these strategies in the out-of-hospital
setting could be substantial, especially in rural communities
remote from the hospital, where the priority is to identify
low-risk individuals suitable for management closer to
home.
In the ED, a variety of risk scores and pathways can
identify the majority of patients with a nonischemic ECG
result as low risk and suitable for discharge, often within a
few hours of presentation.10-13 A more structured out-of-
hospital risk assessment, with or without point-of-care
troponin-level testing, may have even greater importance inAnnals of Emergency Medicine 1
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What is already known on this topic
Accurately triaging emergency medical services
(EMS) patients with suspected acute coronary
syndrome to facilities with the appropriate level of
care could improve outcomes and system efficiency.
What question this study addressed
This prospective EMS cohort study of 1,054 patients
with suspected acute coronary syndrome was
conducted to determine the ability of the HEAR and
HEART score with point-of-care troponin level to
distinguish patients with subsequent 30-day major
adverse cardiac events.
What this study adds to our knowledge
Using a low test threshold, neither the HEAR nor
HEART score was sufficiently sensitive to rule out
subsequent 30-day major adverse cardiac events.
Using a high test threshold, the tests were greater
than 90% specific, but only a small proportion of
patients tested positive.
How this is relevant to clinical practice
Out-of-hospital HEAR and HEART scores provide a
structured approach to assess patients with suspected
acute coronary syndrome. However, their ability to
discriminate patients according to risk of 30-day
major adverse cardiac event is limited.the out-of-hospital setting, where access to experienced
decision makers and other diagnostic resources is limited. If
the accurate and safe identification of low-risk patients
suitable for management without the need for immediate
hospital transfer were possible, this would benefit patients,
stretched emergency medical services, and congested EDs.
The History, ECG, Age, Risk Factors, and Troponin
(HEART) score is an acronym of its component parts.
Each component contributes 0, 1, or 2 points to classify
patients as low (score 3), intermediate (score 4 to 6), or
high risk (score 7).14-17 It is simple to use and data
pertaining to the HEAR components are routinely
collected by paramedics.18 Work from the Netherlands
evaluating the HEART score in an ambulance
demonstrated that the point-of-care cardiac troponin T
testing conferred improved discrimination over clinical
components alone,19 but a score less than or equal to 3 was
still unable to safely rule out myocardial infarction.202 Annals of Emergency MedicineThe objective of this study was to determine the
accuracy of paramedic-derived HEAR and HEART scores
performed in an ambulance to rule out and rule in major
adverse cardiac events at 30 days in patients with suspected
acute coronary syndrome.MATERIALS AND METHODS
Study Design and Setting
A prospective cohort study was performed in the
Grampian region of Scotland, United Kingdom, where 11
ambulance stations cover a rural and urban population of
600,000 across a large geographic area. Aberdeen Royal
Infirmary is the sole tertiary referral hospital for the region.
This study was approved by the National Ethics
Committee, was conducted in accordance with the
Declaration of Helsinki, and adhered to the Strengthening
the Reporting of Observational Studies in Epidemiology
recommendations (Appendix E1, available online at http://
www.annemergmed.com).
This study was performed in accordance with the
National Health Service Scotland’s 2020 vision for health
care delivery21 and relates to one of the major research
priorities identified by patients and practitioners by the
Royal College of Emergency Medicine in conjunction with
the James Lind Alliance.22
Selection of Participants
Patients aged 16 years or older with chest pain attended
by a study-trained paramedic in one of 17 ambulances
fitted with Samsung LABGEOIB10 point-of-care analyzers
(Samsung, Seoul, South Korea) who suspected a diagnosis
of an acute coronary syndrome were eligible for inclusion.
The decision to approach the patient was at the discretion
of the paramedic. Before assessment for inclusion, all
patients underwent a brief clinical history, examination,
and a 12-lead ECG test. Exclusion criteria included
persistent diagnostic ST-segment elevation (>2 mV in V2
and V3 or >1 mV in 2 other contiguous leads)4,23 on the
out-of-hospital ECG, inability to give verbal consent,
pregnancy, refusal to go to the hospital, being in custody,
or previous enrollment in the study within 30 days.
Potential patients were given brief information about the
study before being approached for verbal consent to
participate. Consenting patients had a blood sample drawn
from an intravenous cannula placed in the ambulance by
the attending paramedic who calculated the HEART score
(Table E1, available online at http://www.annemergmed.
com) in the ambulance. The out-of-hospital cardiac
troponin concentrations and HEART scores were not usedVolume -, no. - : - 2021
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to these results. Once in the hospital, patients were
approached for formal written consent to participate in the
study.
Samsung LABGEOIB10 point-of-care analyzers were
fitted into 17 ambulances and regional paramedics
underwent refresher training on cannulation, use of the
Vacutainer (Becton-Dickinson, Franklin Lakes, NJ) system
to draw blood from a cannula, instruction on how to
pipette blood into the test discs, and on operation of the
Samsung analyzers. The training was codesigned and
provided by the Scottish Ambulance Service Learning and
Development Department, the Scottish Centre for
Telehealth and Telecare, and Samsung according to a pilot
program.24 Further training was provided on the principles
of good clinical practice, information governance, and how
to take verbal consent. Bespoke 12-lead ECG training was
provided, as well as scenario-based sessions on clinical chest
pain risk assessment, with reference to the completion of
the HEART score (Table E1, available online at http://
www.annemergmed.com). The attending paramedic used
his or her own interpretation of the history and ECG when
completing the HEART score, and only patient-reported
and available contemporaneous information was used to
calculate the risk factor component.
As recommended by the manufacturers and the National
Health Service Grampian Department of Clinical
Biochemistry, all Samsung analyzers were tested daily with
an internal quality control disc and at intervals with a liquid
cardiac marker quality control material (CLINIQA, San
Marcos, CA). Analyzer logs for each instrument were
completed weekly. An additional independent evaluation of
assay precision was performed monthly through the Wales
External Quality Assurance Scheme for cardiac markers.
The Samsung LABGEOIB point-of-care cardiac
troponin I (cTnI) assay was performed in a 500-mL aliquot
of whole blood in the ambulance. This assay is able to
measure cTnI concentrations between 50 and 3,000 ng/L
and give results within 20 minutes. The manufacturers
report that the 99th centile upper reference limit is 100 ng/
L and the coefficient of variation is 12.6% at this
concentration.25
The out-of-hospital HEART score was calculated as
originally described: troponin I concentration less than or
equal to upper reference limit¼0 points, 1 to 3 times the
upper reference limit¼1 point, and greater than or equal
to 3 times the upper reference limit¼2 points (Table E1,
available online at http://www.annemergmed.com), with
HEART score less than or equal to 3 and greater than or
equal to 7 representing low and high risk, respectively.14-
17 A paramedic HEAR score was also calculated with allVolume -, no. - : - 2021components except troponin level.18 Comparison of
HEART score less than or equal to 3 was made with
HEAR score less than or equal to 3. A HEART score
greater than or equal to 7 was compared with a HEAR
score greater than or equal to 7 and a point-of-care
troponin level greater than the upper reference limit
alone.Outcome Measures
The primary outcome measure was major adverse
cardiac events at 30 days, which included all myocardial
infarction, all coronary revascularization procedures
(percutaneous coronary intervention and coronary artery
bypass grafting), all-cause death, cardiac arrest,
cardiogenic shock, or life-threatening cardiac arrhythmias.
The secondary outcome was a composite of type 1, type
4b, or type 4c myocardial infarction or cardiac death at
30 days. Patients who had not died or remained in the
hospital at 30 days were contacted in order of preference,
by direct telephone call, through their general
practitioner, or through screening of the electronic
patient record.
The standard-of-care test for this study was the
Siemens ADVIA Centaur Ultra contemporary cTnI assay
(Siemens, Munich, Germany). This assay has a limit of
detection of 6 ng/L and an interassay coefficient of
variation of 8.8% at 40 ng/L, the manufacturer’s
recommended 99th centile upper reference limit.26 The
diagnosis of myocardial infarction and cause of death
were adjudicated by 2 cardiologists independently with
access to the standard-of-care assay results, all clinical
information, investigation results, and clinical outcomes
up to 30 days. The adjudicators were not aware of the
HEAR or HEART scores or investigational troponin test
results on the out-of-hospital samples, and any
disagreements were resolved with a third cardiologist
adjudicator. All patients with a standard-of-care cTnI
concentration above the upper reference limit were
adjudicated according to the Fourth Universal Definition
of Myocardial Infarction,27 as previously described.28
Cardiogenic shock was defined as a hypoperfusion state
with evidence of ventricular failure in which the
circulation required sustained mechanical or inotropic
support. Life-threatening arrhythmias were defined as any
ventricular arrhythmia that required emergency
cardioversion or any atrioventricular block that required
an isoprenaline infusion or urgent pacing.
Adjudicated patient population characteristics pertaining
to medical history, previous revascularization, medication
at presentation, and initial ECG result were described inAnnals of Emergency Medicine 3
Table 1. Baseline characteristics of the study population with and without a major adverse cardiovascular event at 30 days.
Descriptor Study Population MACE at 30 Days No MACE at 30 Days
No. 1,054 284 770
Age, mean (SD), y 64 (15) 70 (14) 62 (15)
Women 443 (42) 101 (42) 342 (44)
Medical history
Diabetes mellitus 209 (20) 78 (28) 131 (17)
Hypertension 694 (66) 221 (78) 473 (61)
Hypercholesterolemia 591 (56) 193 (68) 398 (52)
Cerebrovascular disease 118 (11) 42 (15) 76 (10)
Myocardial infarction 296 (28) 95 (34) 201 (26)
Ischemic heart disease 463 (44) 152 (54) 311 (40)
Smoker 219 (21) 63 (22) 156 (20)
Previous revascularization
PCI 202 (19) 65 (23) 137 (18)
CABG 72 (7) 29 (10) 43 (6)
Medication at presentation
Aspirin 377 (36) 114 (40) 263 (34)
Clopidogrel 131 (12) 48 (17) 83 (11)
Other P2Y12 Inhibitor 49 (5) 13 (5) 36 (5)
Statin 545 (52) 176 (62) 369 (48)
ACE inhibitor or ARB 380 (36) 119 (42) 261 (34)
b-Blocker 355 (34) 120 (42) 235 (31)
Oral anticoagulant 115 (11) 42 (15) 73 (10)
ECG*
ST-segment elevation† 11 (1) 9 (3) 2
ST-segment depression 162 (15) 94 (33) 68 (9)
T-wave inversion 130 (12) 63 (22) 67 (9)
Left bundle branch block 108 (10) 47 (17) 61 (8)
Right bundle branch block 106 (10) 27 (10) 79 (10)
Acute ischemia 121 (12) 81 (29) 40 (5)
Normal ECG result 484 (46) 65 (23) 419 (55)
Clinical features
Pulse rate, mean (SD), beats/min 84 (21) 86 (25) 83 (20)
Systolic blood pressure, mean (SD), mm Hg 144 (29) 144 (31) 144 (28)
Chest pain onset to HEAR score, h
3 528 (51) 147 (52) 381 (51)
>3–<12 351 (33) 86 (31) 265 (35)
12 155 (15) 47 (17) 108 (14)
HEAR score, mean (SD) 4.4 (1.7) 5.3 (1.5) 4.1 (1.7)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; MACE, Major adverse
cardiac event.
Data are presented as No. (%) unless otherwise indicated.
*Four patients had missing out-of-hospital ECGs for formal interpretation.
†Eleven patients had ST-segment elevation that was not persistent or diagnostic for ST-segment elevation myocardial infarction.4,23
Ambulance Cardiac Chest Pain Evaluation in Scotland Study Cooper et alline with previous guidance,29 except for cigarette smoking,
which was defined as current or ceased less than 90 days
earlier.154 Annals of Emergency MedicineIn accordance with pooled data from 4 previous
studies,14-17 it was expected that 69% of patients would
have a HEART score greater than 3, of whom 22.3%Volume -, no. - : - 2021
Figure 1. Patient flow diagram. STEMI, ST-elevation myocardial infarction; POC, point of care; GP, general practitioner.
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compared with a 1.6% risk of 30-day major adverse cardiac
events with a HEART score of 0 to 3. Based on these
figures, a study of 1,000 patients would be able to estimate
the sensitivity and specificity of a HEART score greater
than 3 to predict a major adverse cardiac event to the
following levels of accuracy: sensitivity 96.9% (95%
confidence interval [CI] 94.2% to 99.6%) and specificity
36.3% (95% CI 33.1% to 39.5%).
Given that an out-of-hospital population is likely to have
an increased proportion of patients presenting early (less
than 3 hours) from chest pain onset, a caveat for the
implication of ED-based diagnostic strategies,4 a subgroup
analysis of HEART score performance in this group was
planned.
The recently proposed strategy that a HEAR score less
than or equal to 1,30 independent of troponin, may beVolume -, no. - : - 2021appropriate to identify low-risk patients who do not require
further cardiac investigation was evaluated post hoc, along
with the paramedic clinical interpretation of the history
component of the HEART score as low risk in isolation. As
requested during the review process, details of the
nonadjudicated discharge diagnoses are also presented, as is
information regarding those who experienced an important
adjudicated endpoint after index hospital discharge, but
within 30 days.Primary Data Analysis
Data were expressed as frequencies and percentages or as
mean and SD or median with an interquartile range,
depending on normality of distribution. Discrimination of
the HEAR and HEART score for the primary and
secondary composite endpoints was determined by the areaAnnals of Emergency Medicine 5
Figure 2. Clustered bar charts and tables showing frequencies and proportions (with 95% CIs) of the HEAR score in 1,054 patients and
the HEART score in in 357 patients with and without major adverse cardiac events (MACE) at 30 days.
Ambulance Cardiac Chest Pain Evaluation in Scotland Study Cooper et alunder the receiver operator curve (ROC) curve with 95%
CIs. Performance of the HEAR and HEART scores to
identify low- and high-risk patients was evaluated by
constructing 2-by-2 tables and calculating the sensitivity,
specificity, negative predictive value, and positive predictive
value, as well as positive and negative likelihood ratios, of
these thresholds. Statistical analysis was performed with
IBM SPSS (version 25.0; IBM Corp., Armonk, NY).RESULTS
Between November 2014 and April 2018, 85
paramedics obtained verbal consent from 1,275 patients6 Annals of Emergency Medicinewith suspected acute coronary syndrome. Subsequently,
219 patients did not give written consent and 2 patients
withdrew. The remaining 1,054 patients constitute the
study population, of whom 42% were women (443/1,054)
and the mean age was 64 years (SD 15 years) (Table 1).
Although all patients consented to giving a sample for
cardiac troponin measurement in the ambulance, out-of-
hospital point-of-care testing was available only for the first
394 patients. Beyond May 2016, the requisite daily quality
control measures for all 17 instruments could not be
ensured. Paramedics failed to obtain a point-of-care test
result for 37 patients (9%), giving a final sample size of 357
for the evaluation of point-of-care testing (Figure 1). TheVolume -, no. - : - 2021
Table 2. Primary and secondary endpoints during the index presentation and at 30 days in the total study population (n¼1,054).
Descriptor Index Presentation At 30 Days
Adjudicated death
All death 13 (1) 21 (2)
Cardiac death 6 (1) 10 (1)
Adjudicated diagnoses
Myocardial infarction 254 (24) 261 (25)
Type 1 188 (18) 192 (18)
Type 4b 1 2
Type 4c 5 6 (1)
Type 2 60 (6) 63 (6)
Acute myocardial injury 18 (2) 25 (2)
Chronic myocardial injury 7 (1) 8 (1)
Other MACE
PCI 88 (8) 95 (9)
CABG 25 (2) 26 (3)
Thrombolysis 1 1
Cardiac arrest 11 (1) 13 (1)
Ventricular arrhythmia 8 (1) 9 (1)
AV block 4 4
Cardiogenic shock 8 (1) 8 (1)
All MACE* 269 (26) 284 (27)
Type 1 or 4b or 4c myocardial infarction or cardiac death 197 (19) 204 (19)
AV block, Atrioventricular block.
Data are presented as No. (%).
*Major adverse cardiovascular event encompasses death (all cause), myocardial infarction (all types), revascularization (PCI, CABG, or thrombolysis), cardiac arrest, ventricular
arrhythmia (requiring electrocardioversion), AV block (requiring electrical pacing), and cardiogenic shock (a hypoperfusion state with evidence of ventricular failure in which the
circulation required sustained mechanical or inotropic support).
Cooper et al Ambulance Cardiac Chest Pain Evaluation in Scotland Studydistribution of the HEAR score in 1,054 patients and the
HEART score in 357 patients was determined in those
with and without a primary outcome event (Figure 2).
Follow-up was complete in all 1,054 study participants at
30 days.
At 30 days, 27% of patients (284/1,054) had a major
adverse cardiac event, 25% (261/1,054) had any
myocardial infarction, and 2% (21/1,054) had died
(Table 2). The majority of major adverse cardiac events
occurred during the index presentation (95%, 269/284). At
30 days, 19% of patients (204/1,054) had a secondary
outcome of type 1, type 4b, or type 4c myocardial
infarction or cardiac death.
A paramedic HEAR score was available for all 1,054
patients and the area under the ROC for the primary
outcome was 0.70 (95% CI 0.67 to 0.74) (Figure 3).
HEAR score less than or equal to 3 identified 334 patients
(32%) as low risk for 30-day major adverse cardiac events,
with a sensitivity of 84.9% (95% CI 80.7% to 89.0%), andVolume -, no. - : - 2021HEAR score greater than or equal to 7 recognized 118
patients (11%) as high risk, with a specificity 92.9% (95%
CI 91.0 to 94.7%) (Table 3).
The results of HEAR scores less than or equal to 3
and greater than or equal to 7 for the secondary endpoint
were similar to those for major adverse cardiac events
(Table 3).
In 357 patients undergoing out-of-hospital point-of-care
testing, 108 (30%) developed a major adverse cardiac event
(Table E2, available online at http://www.annemergmed.
com) and 85 (24%) a secondary outcome event (Table E3,
available online at http://www.annemergmed.com) at 30
days. With respect to discrimination of the primary
outcome, the area under the ROC was 0.69 (95% CI 0.67
to 0.74) and 0.74 (95% CI 0.68 to 0.79) for the HEAR
and HEART scores, respectively (Figure 3).
A HEAR score less than or equal to 3 identified 116
patients (33%) as low risk for major adverse cardiac events,
with a sensitivity of 81.5% (95% CI 74.2% to 88.8%) andAnnals of Emergency Medicine 7
Figure 3. Discriminatory performance, expressed as area
under the receiver operating curve (AUROC), of HEAR in 1,054
patients and both HEAR and HEART in 357 patients in the
prediction of major adverse cardiac events (MACE) at 30 days.
Ambulance Cardiac Chest Pain Evaluation in Scotland Study Cooper et alnegative predictive value of 82.8% (95% CI 75.9% to
89.6%), whereas a point-of-care HEART score less than or
equal to 3 identified 108 patients (30%), with a sensitivity
of 87.0% (95% CI 80.7% to 93.4%) and negative
predictive value of 87.0% (95% CI 80.7% to 93.4%)
(Table 4).
A HEART score greater than or equal to 7 identified
more patients as high risk than a HEAR score greater than
or equal to 7, 49 (14%) versus 34 (10%), with similar
specificity (94.8% [95% CI 92.0% to 97.5%] versus
95.6% [95% CI 93.0% to 98.1%]) for the primary
outcome. This was similar to a point-of-care troponin level
above the upper reference limit alone, which identified 51
patients (14%) with a specificity of 95.2% (95% CI 92.5%
to 97.8%). Performance was similar for the secondary
outcome (Table 4)
A subgroup analysis of the HEAR score at less than or
equal to 1 and less than or equal to 3 in 528 early
presenters (3 hours) and 526 late presenters (>3 hours)8 Annals of Emergency Medicinewas performed, but did not find any significant difference
either in the proportion of patients identified as low risk or
the sensitivity (Table E4, available online at http://www.
annemergmed.com).
In all 1,054 patients, a HEAR score less than or equal to
1 identified 52 patients (5%) as low risk, with a sensitivity
of 99.3% (95% CI 98.3% to 100%), and a score of 0 for
the interpretable history component of the HEAR score
recognized 278 (26%), with a sensitivity of 87% (95% CI
83.1% to 90.9%) (Table E5, available online at http://
www.annemergmed.com).
The majority of the 770 patients who did not have an
adjudicated outcome event had no sinister cause for their
presentation (Table E6, available online at http://www.
annemergmed.com). However, 2 of the patients with acute
upper abdominal pathology died owing to ischemic small
bowel obstruction (HEAR scores 5 and 6) and 1 patient
had a symptomatic abdominal aortic aneurysm (HEAR
score 5). Six patients had a pulmonary embolism and 4 had
a pneumothorax.
The adjudicated outcomes that occurred in patients
between discharge from the hospital after index
presentation and 30 days are presented in Table 2. Eight
patients in this group died, of whom 4 were adjudicated to
have had a cardiac death. Two patients died suddenly at
home, one after an index type 1 myocardial infarction and
percutaneous coronary intervention, and the other after no
index cardiac event. The remaining 2 patients had been
managed medically for type 1 myocardial infarction during
the index admission and re-presented to hospital and died
of cardiac disease. Of the 10 patients re-presenting with a
type 1 myocardial infarction, 6 had an index episode
diagnosis of myocardial infarction and had been medically
managed and 4 patients had no index event (HEAR scores
5, 6, 7, and 7).LIMITATIONS
Our study had some important strengths and
limitations. First, to our knowledge this is the largest study
to evaluate the HEAR score in the out-of-hospital setting
and involved 85 paramedics serving a large population in
both rural and urban environments. Second, paramedic-
reported HEAR components were available for all 1,054
patients and not derived retrospectively by the researchers.
Third, we chose the primary outcome of a major adverse
cardiac event over myocardial infarction to highlight safety
and capture all clinically important endpoints, but we
recognize that the sentinel question is often, is this patient
having a myocardial infarction? Fourth, follow-up was
complete for all study participants and we did not rely onVolume -, no. - : - 2021

































Cardiac Death at 30 days
No Myocardial Infarction or
Cardiac Death at 30 days
HEAR
score 3












Rule in MACE at 30 Days No MACE at 30 Days
Proportion
High Risk
High Risk Not High Risk High Risk Not High Risk
HEAR
score 7













Cardiac Death at 30 Days
No Myocardial Infarction or
Cardiac Death at 30 Days
HEAR
score 7




















































Table 4. Performance of the HEAR score and HEART score using the Samsung POC cTnI test to predict major adverse cardiovascular events (MACE) and type 1 or 4 myocardial
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Cooper et al Ambulance Cardiac Chest Pain Evaluation in Scotland Studyroutinely collected data, but adjudicated all study
outcomes.
The major limitation was the inability to sustain the
recommended quality control measures in the 17 Samsung
point-of-care instruments across the region, and therefore
this aspect of the study was underpowered. However, given
that the upper limit of the 95% CI for the sensitivity of a
HEART score less than or equal to 3 for both the primary
and secondary outcome was lower than the lower limit of
the 95% CI of our prespecified safety criteria, we believe
our conclusions regarding the rule-out performance of
point-of-care HEART are valid. Paramedics will not be able
to obtain blood on every occasion and, although the
analyzers were generally well accepted into out-of-hospital
clinical practice, there were 26 instances in which an error
code was generated. In addition to being user friendly, new
point-of-care analyzers for out-of-hospital practice need to
be portable, reliable, accurate over a wide variety of
ambient temperatures, and not susceptible to failures on
account of vehicle movement. The other important
limitation was that the decision to approach a patient for
inclusion was necessarily left to the discretion of the
paramedic. Although it would have been ideal to have a
consecutive sample of consenting patients, the reality,
especially in the out-of-hospital setting, is that this is not
feasible. It is possible that the high rate of 30-day major
adverse cardiac events reflects a degree of selection bias, but
the incidence of 30-day myocardial infarction and cardiac
death (20%) is not dissimilar from that of other large
consecutive Scottish cohorts31,32 so we believe our results
are generalizable. Last, the Samsung LABGEO point-of-
care analyzers provided a troponin test result within 20
minutes, and, although newer point-of-care test results are
available in half the time, some may question the usefulness
of such a strategy, particularly in patients from urban
environments close to a hospital. The on-scene time spent
attending a patient with suspected acute coronary
syndrome is 20 minutes,33 and point-of-care testing adds
only 2 minutes to this process,34 so a standardized risk
assessment including point-of-care troponin level may still
add value, even in urban environments, for rule-out,
notwithstanding the ability to rule in myocardial infarction
and allow direct transfer to a specialist cardiac center.DISCUSSION
We prospectively evaluated the clinical utility of a
paramedic-derived HEAR score in 1,054 patients with
chest pain suggestive of an acute coronary syndrome and a
nondiagnostic ECG result. A HEAR score of less than or
equal to 3 identified 1 in 3 patients as low risk, but did notVolume -, no. - : - 2021provide adequate sensitivity or negative predictive value to
rule out major adverse cardiac events in the out-of-hospital
setting. When point-of-care troponin level was available, a
HEART score of greater than or equal to 7 identified more
patients as high risk than a HEAR score greater than or
equal to 7, and with slightly better positive predictive value,
but the performance of out-of-hospital troponin testing
alone was similar. Our findings were similar for the rule-out
of our prespecified primary major adverse cardiac events
outcome and for our secondary outcome of myocardial
infarction or cardiac death.
We demonstrated that the HEART score can be
incorporated into paramedic practice and confirmed
previous work19 showing that out-of-hospital point-of-care
troponin testing improves discrimination over the HEAR
components alone but remains lower than has been
reported in patient populations attending the ED.35
In this study, HEART score less than or equal to 3
identified 30% of patients as low risk, comparable to that
in inhospital studies of the HEART score35 and higher
than that in a previous out-of-hospital cohort.19,20
However, HEART score less than or equal to 3 did not
confer significant benefit over HEAR score less than or
equal to 3, and sensitivity and negative predictive value did
not approach recognized thresholds of 99%36 and
99.5%,31 respectively, for a safe rule-out strategy. In ED
populations, the pooled sensitivity of HEART score less
than or equal to 3 is estimated to be 96.7% (95% CI
94.0% to 98.2%),35 but despite this, incorporation of the
HEART score into rule-out pathways is widespread and
there is randomized trial evidence of reduced length of
stay37,38 and of safety as a singular measurement,39
although health care resource use was not significantly
reduced. Therefore, it was important that this approach be
evaluated in the out-of-hospital setting, where access to
senior medical opinion, diagnostics, and medical records is
limited compared with that in the hospital.
Our post hoc analysis demonstrated that paramedic
interpretation of a low-risk history alone identified 1 in 4
patients, but this approach also had insufficient sensitivity
(performing similarly to HEAR score 3). A HEAR score
less than or equal to 1 had good sensitivity, but recognized
only 1 in 20 patients as low risk, something that may limit
its utility in an out-of-hospital population.
If current approaches do not permit rule-out of
myocardial infarction in the ambulance, can an out-of-
hospital HEART score greater than or equal to 7 identify
high-risk patients for direct transfer to the regional cardiac
center? We found that both HEART score greater than or
equal to 7 and a point-of-care troponin value greater than
the upper reference limit alone identified 1 in 8 patientsAnnals of Emergency Medicine 11
Ambulance Cardiac Chest Pain Evaluation in Scotland Study Cooper et alwith good specificity and positive predictive value for major
adverse cardiac events and myocardial infarction. This
concurs with previous work highlighting that out-of-
hospital point-of-care troponin elevations greater than the
upper reference limit are highly predictive of
mortality7,34,40 and have excellent specificity for myocardial
infarction.6-8,41 Without a point-of-care troponin test, a
HEAR score greater than or equal to 7 identifies a smaller
proportion of patients for rule-in, but with similar
specificity. In any case, although direct transfer of patients
with an out-of-hospital diagnosis of non–ST-segment
elevation myocardial infarction to specialist cardiac centers
may allow earlier revascularization and improved use of
resources, the intuitive clinical benefits of this approach
have not been demonstrated.9,42
The HEART score as first described14 in 2008 and used
in this study recognizes only troponin values above the
upper reference limit. The analytic characteristics of high-
sensitivity cardiac troponin assays now allow the accurate
detection of very small concentrations of troponin, well
below the upper reference limit, to rule out myocardial
infarction and cardiac death at 30 days with negative
predictive value greater than 99.5% in patients presenting
to the ED at least 2 hours from symptom onset.31,32 Might
such an approach be extended to the out-of-hospital setting
with newer point-of-care assays that have analytic
properties similar to those of established high-sensitivity
assays on laboratory platforms?43-45 The HEART score has
also correspondingly evolved to incorporate very low
concentrations of troponin, with a new iteration defining
the high-sensitivity troponin component as 0 points if
below the limit of detection, 1 point if between the limit of
detection and the upper reference limit, and 2 points if
above the upper reference limit. The initial results of this
strategy are promising46 and may increase the safety of the
HEART score to rule out patients in the ED. Whatever
approach is evaluated, it will have to account for a
significant proportion of patients presenting early and is
likely to require a repeated troponin test. However, for
patients presenting greater than or more than 3 hours from
chest pain onset, if point-of-care troponin tests can reliably
attain the diagnostic performance of laboratory high-
sensitivity tests in the out-of-hospital setting, then rule-out
of myocardial infarction may be possible in selected low-
risk populations.
Other than effectiveness of such an approach, patient
safety is paramount, with access to the same quality of
assessment, decisionmaking, and follow-up offered in the
hospital. Our results demonstrate that, having excluded
myocardial infarction, a clinician has to carefully consider
other serious causes for chest pain and the patient’s12 Annals of Emergency Medicinephysiologic and social status. This assessment could feasibly
be carried out in primary care, but would need resourced,
secondary care support and robust evaluation.47-49
Paramedics can use the HEAR score to discriminate risk,
but even when used in combination with out-of-hospital
point-of-care cardiac-troponin-level testing, the HEART
score does not safely rule outmajor adverse cardiac events, and
only a small proportion of patients are identified as high risk.
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